Block Grant R15AI058989

The National Institutes of Health Office of the Director awarded a $2,767,566 Trans-NIH Research Support project grant to the University of Pittsburgh to develop Signaling and Antigen-Presenting Bifunctional Receptors (SABRs) as an immune engineering platform. SABRs consist of extracellular full-length MHC complexes genetically linked to epitopes and fused with intracellular signaling domains. This allows SABRs to present epitopes to T cells while eliciting intracellular signaling upon...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,269,762 in funding to Northwestern University to develop a novel microfluidic platform for high-performance sorting of immune cells based on their distinct secretion patterns. The goal of this 5-year project is to leverage the university's "SECRE" (Secretion-Enabled Cell Ranking and Enrichment)...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $246,623 to New York University School of Medicine to conduct research on the molecular control of tolerogenic dendritic cell function. The research aims to identify the specific dendritic cell subset responsible for maintaining T cell tolerance, characterize the molecular basis of its tolerogenic function, and...

This $812,810 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research at Emory University to generate highly differentiated natural killer (NK) cells and evaluate their synergistic effects with broadly neutralizing antibodies in reducing the SIV reservoir and establishing viral control in the absence of antiretroviral therapy (ART). The key objectives are to: 1) define...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $231,345 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, San Diego (UCSD). The central focus of this 2-year project, with an award period of January 15, 2025 to December 31, 2026, is to define the contribution of heparan sulfate to the tissue-specific regulation of complement, a key immune system mechanism. The research will utilize a combination...

This $811,009 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop a novel microfluidic platform called the Shear-Force Avidity-based Cell Selector (SACS) to rapidly assess the functional immune status of individuals by quantifying the binding avidity of antigen-specific memory B cells. The primary objectives are to: 1) enhance and optimize the...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $276,450 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to The Salk Institute for Biological Studies to study the role of PPARδ-controlled CIITA/MHCII expression in regulatory T cells (Tregs) and its impact on tumor immunity. The research aims to define the molecular mechanisms by which MHCII expression in Tregs is regulated by the PPARδ/CIITA axis, and to characterize the in vivo consequences...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is funding research conducted by the Scripps Research Institute to identify small molecule compounds that can selectively induce the differentiation of functional regulatory T cells (Tregs). The research aims to address challenges in expanding Treg populations without unintended immunosuppressive effects. The $417,984 award,...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $799,017 to Emory University to conduct research on generating highly differentiated natural killer (NK) cells that can synergize with broadly neutralizing antibodies to establish viral control in the absence of antiretroviral therapy (ART). The key objectives of this 5-year research project are to: 1) define...

The National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health, awarded a $169,500 Project Grant (CFDA 93.350) to the Weill Medical College of Cornell University. The project, titled "Modulation of CD8+ T Cell Differentiation and Anti-Tumor Immunity by Metabolic Manipulation," aims to identify metabolic enzymes that control the generation of TCF1+ progenitor CD8+ T cells, a subset critical for effective anti-tumor immune responses. The...